PHARMING GROUP NV (PHARM.AS) Fundamental Analysis & Valuation

AMS:PHARM • NL0010391025

Current stock price

1.444 EUR
+0.03 (+2.41%)
Last:

This PHARM.AS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. PHARM.AS Profitability Analysis

1.1 Basic Checks

  • PHARM had negative earnings in the past year.
  • In the past year PHARM had a positive cash flow from operations.
  • In multiple years PHARM reported negative net income over the last 5 years.
  • In multiple years PHARM reported negative operating cash flow during the last 5 years.
PHARM.AS Yearly Net Income VS EBIT VS OCF VS FCFPHARM.AS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M

1.2 Ratios

  • PHARM has a better Return On Assets (0.56%) than 67.50% of its industry peers.
  • PHARM's Return On Equity of 1.02% is fine compared to the rest of the industry. PHARM outperforms 72.50% of its industry peers.
  • The Return On Invested Capital of PHARM (6.27%) is better than 78.75% of its industry peers.
Industry RankSector Rank
ROA 0.56%
ROE 1.02%
ROIC 6.27%
ROA(3y)-1.56%
ROA(5y)0.51%
ROE(3y)-3.05%
ROE(5y)1.16%
ROIC(3y)N/A
ROIC(5y)N/A
PHARM.AS Yearly ROA, ROE, ROICPHARM.AS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300 -400

1.3 Margins

  • With a decent Profit Margin value of 0.75%, PHARM is doing good in the industry, outperforming 68.75% of the companies in the same industry.
  • In the last couple of years the Profit Margin of PHARM has declined.
  • PHARM has a Operating Margin of 8.54%. This is in the better half of the industry: PHARM outperforms 76.25% of its industry peers.
  • In the last couple of years the Operating Margin of PHARM has declined.
  • PHARM has a Gross Margin of 87.91%. This is in the better half of the industry: PHARM outperforms 77.50% of its industry peers.
  • In the last couple of years the Gross Margin of PHARM has remained more or less at the same level.
Industry RankSector Rank
OM 8.54%
PM (TTM) 0.75%
GM 87.91%
OM growth 3Y19.35%
OM growth 5Y-24.92%
PM growth 3Y-51.51%
PM growth 5Y-46.8%
GM growth 3Y-1.31%
GM growth 5Y-0.23%
PHARM.AS Yearly Profit, Operating, Gross MarginsPHARM.AS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. PHARM.AS Health Analysis

2.1 Basic Checks

  • PHARM has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • The number of shares outstanding for PHARM has been increased compared to 1 year ago.
  • The number of shares outstanding for PHARM has been increased compared to 5 years ago.
  • The debt/assets ratio for PHARM has been reduced compared to a year ago.
PHARM.AS Yearly Shares OutstandingPHARM.AS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M
PHARM.AS Yearly Total Debt VS Total AssetsPHARM.AS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

2.2 Solvency

  • Based on the Altman-Z score of 1.03, we must say that PHARM is in the distress zone and has some risk of bankruptcy.
  • PHARM has a Altman-Z score (1.03) which is comparable to the rest of the industry.
  • The Debt to FCF ratio of PHARM is 2.15, which is a good value as it means it would take PHARM, 2.15 years of fcf income to pay off all of its debts.
  • PHARM has a better Debt to FCF ratio (2.15) than 91.25% of its industry peers.
  • PHARM has a Debt/Equity ratio of 0.39. This is a healthy value indicating a solid balance between debt and equity.
  • PHARM's Debt to Equity ratio of 0.39 is fine compared to the rest of the industry. PHARM outperforms 62.50% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.39
Debt/FCF 2.15
Altman-Z 1.03
ROIC/WACC1.01
WACC6.2%
PHARM.AS Yearly LT Debt VS Equity VS FCFPHARM.AS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M 200M 250M

2.3 Liquidity

  • A Current Ratio of 2.59 indicates that PHARM has no problem at all paying its short term obligations.
  • PHARM has a Current ratio (2.59) which is in line with its industry peers.
  • PHARM has a Quick Ratio of 2.03. This indicates that PHARM is financially healthy and has no problem in meeting its short term obligations.
  • PHARM's Quick ratio of 2.03 is in line compared to the rest of the industry. PHARM outperforms 50.00% of its industry peers.
Industry RankSector Rank
Current Ratio 2.59
Quick Ratio 2.03
PHARM.AS Yearly Current Assets VS Current LiabilitesPHARM.AS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. PHARM.AS Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 111.11% over the past year.
  • Measured over the past years, PHARM shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -48.41% on average per year.
  • The Revenue has grown by 26.55% in the past year. This is a very strong growth!
  • The Revenue has been growing by 12.13% on average over the past years. This is quite good.
EPS 1Y (TTM)111.11%
EPS 3Y-40.82%
EPS 5Y-48.41%
EPS Q2Q%60%
Revenue 1Y (TTM)26.55%
Revenue growth 3Y22.3%
Revenue growth 5Y12.13%
Sales Q2Q%14.96%

3.2 Future

  • PHARM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 157.07% yearly.
  • PHARM is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.57% yearly.
EPS Next Y1877.6%
EPS Next 2Y329.38%
EPS Next 3Y213.1%
EPS Next 5Y157.07%
Revenue Next Year8.86%
Revenue Next 2Y5.74%
Revenue Next 3Y2.04%
Revenue Next 5Y12.57%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
PHARM.AS Yearly Revenue VS EstimatesPHARM.AS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M
PHARM.AS Yearly EPS VS EstimatesPHARM.AS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.1 -0.1 0.2

More info and screens

Find the best growth stocksShow best growing peers

5

4. PHARM.AS Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Forward Earnings ratio is 41.93, which means the current valuation is very expensive for PHARM.
  • PHARM's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. PHARM is cheaper than 72.50% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 22.10. PHARM is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 41.93
PHARM.AS Price Earnings VS Forward Price EarningsPHARM.AS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

  • PHARM's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. PHARM is cheaper than 97.50% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, PHARM is valued cheaply inside the industry as 98.75% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 2.14
EV/EBITDA 0.36
PHARM.AS Per share dataPHARM.AS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3 4

4.3 Compensation for Growth

  • PHARM's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • PHARM's earnings are expected to grow with 213.10% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y329.38%
EPS Next 3Y213.1%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PHARM.AS Dividend Analysis

5.1 Amount

  • No dividends for PHARM!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PHARM.AS Fundamentals: All Metrics, Ratios and Statistics

PHARMING GROUP NV

AMS:PHARM (3/31/2026, 5:07:09 PM)

1.444

+0.03 (+2.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-12
Earnings (Next)05-07
Inst Owners24.69%
Inst Owner ChangeN/A
Ins Owners1.35%
Ins Owner ChangeN/A
Market Cap100.60M
Revenue(TTM)376.10M
Net Income(TTM)2.82M
Analysts88.57
Price Target2.19 (51.66%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)532.06%
Min EPS beat(2)-6.76%
Max EPS beat(2)1070.87%
EPS beat(4)2
Avg EPS beat(4)286.26%
Min EPS beat(4)-42.39%
Max EPS beat(4)1070.87%
EPS beat(8)3
Avg EPS beat(8)81.54%
EPS beat(12)5
Avg EPS beat(12)48.19%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.28%
Min Revenue beat(2)-1.68%
Max Revenue beat(2)1.11%
Revenue beat(4)3
Avg Revenue beat(4)5.37%
Min Revenue beat(4)-1.68%
Max Revenue beat(4)13.37%
Revenue beat(8)4
Avg Revenue beat(8)0.36%
Revenue beat(12)7
Avg Revenue beat(12)0.29%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)4.88%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)-95%
EPS NY rev (1m)51.18%
EPS NY rev (3m)0.63%
Revenue NQ rev (1m)0.81%
Revenue NQ rev (3m)0.81%
Revenue NY rev (1m)-0.34%
Revenue NY rev (3m)6.48%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 41.93
P/S 0.31
P/FCF 2.14
P/OCF 2.11
P/B 0.42
P/tB 0.82
EV/EBITDA 0.36
EPS(TTM)0
EYN/A
EPS(NY)0.03
Fwd EY2.39%
FCF(TTM)0.67
FCFY46.7%
OCF(TTM)0.68
OCFY47.35%
SpS4.7
BVpS3.46
TBVpS1.77
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 0.56%
ROE 1.02%
ROCE 8.36%
ROIC 6.27%
ROICexc 11.75%
ROICexgc 34.65%
OM 8.54%
PM (TTM) 0.75%
GM 87.91%
FCFM 14.35%
ROA(3y)-1.56%
ROA(5y)0.51%
ROE(3y)-3.05%
ROE(5y)1.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y55.24%
ROICexgc growth 5Y-23.76%
ROICexc growth 3Y34.03%
ROICexc growth 5Y-22.4%
OM growth 3Y19.35%
OM growth 5Y-24.92%
PM growth 3Y-51.51%
PM growth 5Y-46.8%
GM growth 3Y-1.31%
GM growth 5Y-0.23%
F-Score6
Asset Turnover0.75
Health
Industry RankSector Rank
Debt/Equity 0.39
Debt/FCF 2.15
Debt/EBITDA 2.47
Cap/Depr 6.73%
Cap/Sales 0.2%
Interest Coverage 5.18
Cash Conversion 126.22%
Profit Quality 1911.19%
Current Ratio 2.59
Quick Ratio 2.03
Altman-Z 1.03
F-Score6
WACC6.2%
ROIC/WACC1.01
Cap/Depr(3y)6.96%
Cap/Depr(5y)24.22%
Cap/Sales(3y)0.36%
Cap/Sales(5y)2.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)111.11%
EPS 3Y-40.82%
EPS 5Y-48.41%
EPS Q2Q%60%
EPS Next Y1877.6%
EPS Next 2Y329.38%
EPS Next 3Y213.1%
EPS Next 5Y157.07%
Revenue 1Y (TTM)26.55%
Revenue growth 3Y22.3%
Revenue growth 5Y12.13%
Sales Q2Q%14.96%
Revenue Next Year8.86%
Revenue Next 2Y5.74%
Revenue Next 3Y2.04%
Revenue Next 5Y12.57%
EBIT growth 1Y472.59%
EBIT growth 3Y45.97%
EBIT growth 5Y-15.82%
EBIT Next Year4.45%
EBIT Next 3Y48.37%
EBIT Next 5Y57.73%
FCF growth 1Y2182.32%
FCF growth 3Y38.11%
FCF growth 5Y-4.61%
OCF growth 1Y3147.8%
OCF growth 3Y34.55%
OCF growth 5Y-8.14%

PHARMING GROUP NV / PHARM.AS Fundamental Analysis FAQ

What is the ChartMill fundamental rating of PHARMING GROUP NV (PHARM.AS) stock?

ChartMill assigns a fundamental rating of 5 / 10 to PHARM.AS.


What is the valuation status for PHARM stock?

ChartMill assigns a valuation rating of 5 / 10 to PHARMING GROUP NV (PHARM.AS). This can be considered as Fairly Valued.


Can you provide the profitability details for PHARMING GROUP NV?

PHARMING GROUP NV (PHARM.AS) has a profitability rating of 4 / 10.